Source comparison
Tesamorelin Body Composition Complete Guide 2026: Comparison Table
Before using tesamorelin, understand how it compares to other body composition interventions targeting visceral fat. Tesamorelin 2mg daily GHRH analogue. Stimulates pulsatile GH release 15–20% (selective) No change Injection site reactions (30%), transient glu
This comparison does not assign a generated winner or score.
- Before using tesamorelin, understand how it compares to other body composition interventions targeting visceral fat.
- Tesamorelin 2mg daily
- GHRH analogue. Stimulates pulsatile GH release
- 15–20% (selective)
- No change
- Injection site reactions (30%), transient glucose elevation, joint pain (12%)
- Most anatomically selective VAT intervention available. Works independent of caloric restriction but requires daily injection
- GLP-1 agonists (semaglutide)
- Appetite suppression + delayed gastric emptying
- 8–12% (non-selective)
- Significant reduction
- GI side effects (40%), dose titration required
- Superior total fat loss but non-selective. Reduces both VAT and SAT equally
- Caloric restriction (500 kcal deficit)
- Energy imbalance → lipolysis
- 10–15% (non-selective)
- Metabolic adaptation, hunger, adherence challenges
- Effective but difficult to sustain long-term. VAT and SAT both reduced
- Growth hormone (exogenous)
- Direct GH receptor activation
- 12–18% (selective)
- Minimal reduction
- Insulin resistance, joint pain, edema, carpal tunnel risk
- More potent than tesamorelin but higher adverse event rate and loss of physiological pulsatility
- Metformin 2000mg daily
- AMPK activation, improved insulin sensitivity
- 3–6% (minimal)
- GI distress (25%), lactic acidosis risk (rare)
- Modest VAT effect. Primarily a glucose management tool, not a fat loss intervention